IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting
April 26, 2023 10:00 ET
|
IN8bio, Inc
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced an...
IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma
April 25, 2023 08:00 ET
|
IN8bio, Inc
First-ever orphan drug designation for genetically modified gamma-delta T cell therapies This orphan drug designation offers potential 7-year market exclusivity for both autologous (INB-400) and...
IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023
April 24, 2023 08:00 ET
|
IN8bio, Inc
INB-100 treatment has achieved durable 100% complete remission (CR) in treated patients, including high-risk acute myeloid leukemia (AML) patients and a patient with acute lymphoblastic leukemia (ALL)...
IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023
April 17, 2023 09:00 ET
|
IN8bio, Inc
INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target cancer cells while sparing healthy tissue when both express the CAR-targeted antigen.CAR...
IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting
April 11, 2023 08:00 ET
|
IN8bio, Inc
Updated data on durability of responses and long-term complete responses (CRs) in leukemia patients treated with INB-100 will be presented; no dose-limiting toxicities have been observedNew...
IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
March 30, 2023 16:15 ET
|
IN8bio, Inc
All Cohort 1 leukemia patients have maintained durable morphological complete responses (CR) beyond 18 months and up to 2.7 years in an ongoing Phase 1 trial of INB-100 as of December 9, 2022; Updated...
IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023
March 16, 2023 08:00 ET
|
IN8bio, Inc
INB-300, a gamma-delta T cell based chimeric antigen receptor (CAR) platform, demonstrated the ability to target malignant cells while preserving healthy tissue. Data supports the potential for this...
IN8bio to Present at the Cowen 43rd Annual Healthcare Conference
March 01, 2023 08:00 ET
|
IN8bio, Inc
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today...
IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue
February 23, 2023 07:00 ET
|
IN8bio, Inc
Next-generation gamma-delta T cell CAR technology targets tumors while sparing healthy tissue. Greater than 15x difference in killing between tumor cells and healthy B cells with the non-signaling...
IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference
February 21, 2023 07:00 ET
|
IN8bio, Inc
NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today...